Irinotecan as a second-line monotherapy for small cell lung cancer

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 4, 2011, Pages 1055-1059

  Sevinc, Alper ^a   Kalender, Mehmet Emin ^a   Altinbas, Mustafa ^b   Ozkan, Metin ^c   Dikilitas, Mustafa ^c   Camci, Celalettin ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c ERCIYES UNIVERSITY   (Turkey)

Author keywords

Irinotecan; Second line chemotherapy; Small cell lung cancer; Survival

Indexed keywords

EID: 84856238397     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Chen G, Huynh M, Chen A, et al (2008). Chemotherapy for brain metastases in small-cell lung cancer. Clin Lung Cancer, 9, 35.
2. Chen G, Huynh M, Fehrenbacher L, et al (2009). Phase II trial of irinotecan and carboplatin for extensive or relapsed smallcell lung cancer. J Clin Oncol, 27, 1401-4.
3. DeVore RF, Blanke CD, Denham CA, et al (1998). Phase II study of irinotecan (CPT-11) in patients with previously treated small cell lung cancer (SCLC). Proc Am Soc Clin Oncol, 17, 451a.
4. Ettinger DS (2001). New drugs for chemotherapy-naive patients with extensivedisease small cell lung cancer. Semin Oncol, 28, 27-9.
5. Feld R, Evans WK, DeBoer G, et al (1984). Combined modality induction therapy without maintenance chemotherapy for small cell carcinoma of the lung. J Clin Oncol, 2, 294-304.
6. Govindan R, Page N, Morgensztern D, et al (2006). Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol, 24, 4539-44.
7. Hande KR, Des Prez RM (1984). Current perspectives in small cell lung cancer. Chest, 85, 669-77.
8. Hattori Y, Shi L, Ding W, et al (2009). Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors. J Control Release, 136, 30-7.
9. Hershman D, Weinberg M, Rosner Z, et al (2003). Ethnic neutropenia and treatment delay in African American women undergoing chemotherapy for early-stage breast cancer. J Natl Cancer Inst, 95, 1545-8.
10. Jackman DM, Johnson BE (2005). Small-cell lung cancer. Lancet, 366, 1385-96.
11. Jemal A, Tiwari RC, Murray T, et al (2004). Cancer statistics 2004. CA Cancer J Clin, 54, 8-29.
12. Jemal A, Siegel R, Ward E, et al (2007). Cancer statistics, 2007. CA Cancer J Clin, 57, 43-66.
13. Kelly K (2000). New chemotherapy agents for small cell lung cancer. Chest, 117, 156S-62S.
14. Kim HG, Lee GW, Kang JH, et al (2008). Combination chemotherapy with irinotecan and cisplatin in elderly patients (≥ 65 years) with extensive-disease small-cell lung cancer. Lung Cancer, 61, 220-6.
15. Kirsch DG, Ledezma CJ, Mathews CS, et al (2005). Survival after brain metastases from breast cancer in the trastuzumab era. J Clin Oncol, 23, 2114-6.
16. Le Chevalier T, Ibrahim N, Chomy P, et al (1997). A phase II study of irinotecan (CPT-11) in patients (pts) with small cell lung cancer (SCLC) progressing after initial response to first-line chemotherapy (CT) (Meeting abstract). Proc Am Soc Clin Oncol, 16.
17. Lower EE, Drosick DR, Blau R, et al (2003). Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival. Clin Breast Cancer, 4, 114-9.
18. Masuda N, Fukuoka M, Kusunoki Y, et al (1992). CPT-11:a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol, 10, 1225-9.
19. Morstyn G, Ihde DC, Lichter AS, et al (1984). Small cell lung cancer 1973-1983: early progress and recent obstacles. Int Radiat Oncol Biol Phys, 10, 515-39.
20. Negoro S, Fukuoka M, Niitani H, et al (1991). A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group. Gan To Kagaku Ryoho, 18, 1013-9.
21. Noda K, Nishiwaki Y, Kawahara M, et al (2002). Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med, 346, 85-91.
22. Noordijk EM, Vecht CJ, Haaxma-Reiche H, et al (1994). The choice of treatment of a single brain metastasis should be based on extra-cranial tumor activity and age. Int J Radiat Oncol Biol Phys, 29, 711-7.
23. Ohyanagi F, Horiike A, Okano Y, et al (2008). Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer. Cancer Chemother Pharmacol, 61, 503-8.
24. Oldham RK, Greco FA (1980). Small-cell lung cancer: a curable disease. Cancer Chemother Pharmacol, 4, 173-7.
25. Pallis AG, Agelidou A, Agelaki S, et al (2009). Multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer. Lung Cancer, 65, 187-91.
26. Spiro SG (1985). Chemotherapy for small cell lung cancer. Br Med J, 290, 413-4.
27. Von PJ, Schiller JH, Shepherd FA, et al (1999). Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol, 17, 658-67.